In 2012, MSF treated 1,440 people for chagas disease.

Chagas is not as well known as diseases such as malaria or cholera yet it affects between six and seven million people and kills up to 12,500 each year.

In 2012, MSF treated 1,440 people for chagas disease.

Chagas is a parasitic disease found almost exclusively on the American continent, though with increases in global travel cases have begun to be reported in the US and Europe.

Millions of people with the disease, including those infected decades ago, go undetected and untreated. Without treatment, chagas can eventually progress to fatally damaging the heart, nervous and digestive systems.

MSF has treated patients with chagas disease since 1999 and has worked in Bolivia, Guatemala, Honduras, Mexico, Brazil and Nicaragua. However, existing drugs and diagnostic tests are inadequate, expensive and in short supply.

Without significant funding, MSF chagas programmes in Latin America have an uncertain future.

MSFs Impact

Chagas, or Trypanosoma cruzi, is a parasitic disease transmitted by an insect that lives in the walls and roofs of mud and straw housing, common in rural areas and urban slums in Latin America.

The bugs that carry the disease, known as ‘triatomines’, emerge at night to feed. Chagas has also been known to be transmitted through blood transfusions, organ transplants, breast feeding and congenitally, through a pregnant mother to her baby.

Contracting the disease through eating or drinking infected food or water is highly unusual but it has been recorded.

Chagas disease has two stages: an acute stage, shortly after infection and a chronic stage, developing over many years. Detecting chagas in both stages is particularly difficult.

In the acute stage - the first few weeks after infection - only mild symptoms show which are common in many other diseases. These can range from body aches and fatigue to fever and vomiting.

After the acute phase, chagas goes into remission and no other symptoms may appear for many years.

About 20 to 30 per cent of those infected will go on to develop the chronic form of the disease where life-threatening heart and/or digestive disorders will develop, causing irreversible damage to the heart, oesophagus and colon. Symptoms at this stage might include constipation, digestive problems, pain in the abdomen and swallowing difficulties.

Diagnosing the disease is complicated. Doctors need to perform two or three blood tests to determine whether the patient is infected with the parasite and often these tests are inadequate, expensive and in short supply. MSF has called for the development of new diagnostic tests.

Treatment must occur in the acute stage of the infection, and because people who have been treated can easily be re-infected, treatment is more effective in areas with active vector control (the vector in this case being the insect that transmits the disease). To date, drugs have only been effective in the acute and asymptomatic stage of the disease.

There are few drugs that can effectively treat the disease and the current line of treatment can be toxic, taking one to two months to complete. Just like diagnostic tests for chagas, treatments for the disease are also inadequate and expensive.

In Bolivia and Guatemala, MSF’s most effective chagas programmes have focused on preventative measures, education and screening in children.

In 2012, MSF treated 1,440 people for chagas disease.

A patient getting treated for Kala Azar by MSF staff in Ethiopia
Neglected Tropical Diseases

No more neglected diseases, no more neglected patients

Report 28 Jan 2021
Sleeping Sickness

Neglected Tropical Diseases

Latest News 30 Jan 2020
Buruli Ulcer

Rohingya Refugees: “I have never seen so much suffering in my entire life”

Fieldworkers Stories 29 Dec 2017
SGBV Medical Emergency Haiti
Buruli Ulcer

MAIL AND GUARDIAN: Women refugees take contraceptives in fear of rape

Latest News 1 Dec 2016
Videos and Photos

EMOCHA Chagas intervention in Bolivia

23 Nov 2016
Videos and Photos
Fatal Neglect Chagas Seamus Murphy

Deadly gaps persist in new drug development for neglected diseases

Press Release 24 Oct 2013